DelveInsight has launched a new report on “Type 2 Diabetes – Market Insights, Epidemiology, and Market Forecast-2032”.
Some of the key facts of the Type 2 Diabetes Market Report:
- A per a study conducted by Nordström et al. (2016), to investigate the prevalence of diabetes in older men and women in relation to objectively assessed visceral fat volume, the prevalence of type 2 diabetes was 14.6% in men and 9.1% in women (p < 0.001). Mean BMI was slightly higher in men than in women (27.3 vs. 26.6 kg/m2; p = 0.01), with a greater difference in mean visceral fat mass (1,987 vs. 1,077 g; p < 0.001). After adjustment for physical activity and smoking, men had about/approximately twice the odds of having type 2 diabetes compared with women (odds ratio [OR], 1.95; 95% confidence interval [CI], 1.38–2.76). The inclusion of BMI in this model did not change the risk associated with male (OR, 1.93; 95% CI, 1.34–2.77).
- In Germany, a research study was conducted wherein, the mean ± sd age at Type 2 diabetes diagnosis in 2015 was 61.0 ± 13.4 years (95% CI 60.9–61.0) in men. Women were diagnosed ~2 years later than men (mean age 63.4 ± 14.9 years; 95% CI 63.4–63.5). The age range in which 50% of the population was diagnosed with diabetes was 53–72 years for men and 54–76 years for women. Jacobs et al. (2019).
Key benefits of the report:
- Type 2 Diabetes market report covers a descriptive overview and comprehensive insight of the Type 2 Diabetes Epidemiology and Type 2 Diabetes market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Type 2 Diabetes market report provides insights on the current and emerging therapies.
- Type 2 Diabetes market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Type 2 Diabetes market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Type 2 Diabetes market.
Type 2 Diabetes Overview
Diabetes is a chronic metabolic condition characterized by high or low blood glucose (or blood sugar) levels, leading to significant damage to the heart, blood vessels, eyes, kidneys, and nerves over time. The rationale behind developing diabetes incorporates two factors: insufficient insulin production (produced by the pancreas and reduced blood glucose) or unsatisfactory cell response to insulin action.
Clinically, diabetes is classified into three types, type 1 diabetes (TD-1), type 2 diabetes (TD2), and gestation diabetes. TD1 is the consequence of an autoimmune reaction that causes the pancreas to suppress insulin-producing β-cells and leads to a severe insulin deficiency. TD2 is linked with a genetic factor, which is far more common and substantially correlates with obesity and unhealthy lifestyles. Insulin resistance (inadequate reaction of peripheral cells to insulin) and pancreatic β-cell dysfunction (impaired insulin secretion) are marked by type 2 diabetes, leading to relative insulin deficiency.
Type 2 diabetes, the most common type of diabetes, it is a disease that occurs when the blood glucose, also called blood sugar, is too high. People who are middle-aged or older are most likely to get this kind of diabetes. It used to be called adult-onset diabetes. But type 2 diabetes also affects kids and teens, mainly because of childhood obesity.
Type 2 Diabetes Market
The dynamics of the Type 2 Diabetes market is anticipated to change in the coming years owing to the expected launch of emerging therapies by companies such as Bayer, Eli Lilly and Company, Oramed and AstraZeneca, and others during the study period 2019-2032.
Type 2 Diabetes Pipeline Therapies and Key Companies
- Finerenone (BAY 94-8862: Bayer
- LY3298176: Eli Lilly and Company
- ORMD-0801: Oramed
- AZD9567: AstraZeneca
- And others.
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Type 2 Diabetes Patient Share (%) Overview at a Glance
5. Type 2 Diabetes Market Overview at a Glance
6. Type 2 Diabetes Disease Background and Overview
7. Type 2 Diabetes Epidemiology and Patient Population
8. Country-Specific Patient Population of Type 2 Diabetes
9. Type 2 Diabetes Current Treatment and Medical Practices
10. Unmet Needs
11. Type 2 Diabetes Emerging Therapies
12. Type 2 Diabetes Market Outlook
13. Country-Wise Type 2 Diabetes Market Analysis (2019–2032)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Type 2 Diabetes Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Request for a detailed sample report @https://www.delveinsight.com/sample-request/type-2-diabetes-market
Related Reports:
Type 2 Diabetes Pipeline
“Type 2 Diabetes Pipeline Insight, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Type 2 Diabetes market. A detailed picture of the Type 2 Diabetes pipeline landscape is provided, which includes the disease overview and Type 2 Diabetes treatment guidelines.
Type 2 Diabetes Epidemiology
DelveInsight’s ‘Type 2 Diabetes Epidemiology Forecast to 2032’ report delivers an in-depth understanding of the disease, historical and forecasted Type 2 Diabetes epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/